Psychedelic Therapeutics Market: By Source (Natural Psychedelic Substance, Synthetic Psychedelic Substance), By Drug Type (Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide, 3,4-MethylEnedioxyMethamphetamine, Others), By Application (Treatment-Resistant Depression, Opiate Addiction, Post-traumatic Stress Disorder, Narcolepsy, and Panic Disorder, Others), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Psychedelic Therapeutics Market was valued at USD 2,840.6 million in 2022 and is expected to grow at a 13.9% CAGR from 2023 to 2029. The psychedelic drugs are the drugs which has the ability to change or enhance the sensory perception, energy levels, thought processes, and it has also been reported to facilitate spiritual experiences. The psychedelic drugs have wide applications in the treatment of major depressive disorder, panic disorder, post-traumatic stress disorder, opiate addiction. The psychedelic drugs have shown a large popularity and had a positive impact on human mental healing. Continuous research and development in psychedelic drugs have increased the acceptance of psychedelic medications which is expected to drive the growth of psychedelic therapeutics market over the forecast period.

In addition, increasing prevalence of depression and mental disorders along with increasing awareness of people towards mental health is expected to boost the growth of psychedelic therapeutics market over the forecast period. For instance, in May 2022, Mental Health Foundation conducted mental health awareness program under the theme loneliness, as it is anticipated to explore the experience of loneliness, its effect on mental health, and how people can all play a part in reducing loneliness in the communities. However, the high cost of psychedelic drugs along with the strict rules and regulations regarding the psychedelic drugs are expected to hold back and hinder the growth of psychedelic therapeutics market over the forecast period. Moreover, the growing research and development activities in the development of psychedelic drugs along with the increasing product approvals are expected to provide opportunities to the market players in the growth of psychedelic therapeutics market over the forecast period. For instance, In August 2020, Janssen Pharmaceuticals, Inc. received FDA approval for its Spravato nasal spray indicated for treatment of suicidal people.  

Psychedelic Therapeutics Market Key Developments:

In September 2019, Johns Hopkins Medicine launched the center for psychedelic and consciousness research to study how compounds like psilocybin and LSD can be used in the treatment of anorexia, depression, addiction, and other mental health issues.

Psychedelic Therapeutics Market Summary

Study Period

2023-29

Base Year

2022

CAGR

13.9%

Largest Market

North America

Fastest Growing Market

North America
Psychedelic Therapeutics Market Dynamics

The psychedelic therapeutic market is expected to grow over the forecasted period due to the increasing interest and acceptance of alternative therapies for mental health disorders. Traditional pharmaceutical treatment for conditions such as depression, anxiety, and PTSD have limitations and can cause unwanted side effects. As a result, there is a growing demand for alternative treatment which can provide relief without any side effects. In addition, psychedelic drugs such as psilocybin, MDMA-assisted therapy have shown a positive result in the clinical trials for treating these mental disorders which is expected to drive the growth of psychedelic therapeutic market at a significant rate over the forecast period.

Key Features of the Reports

  • The psychedelic therapeutics market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

Psychedelic Therapeutics Market Segmentation

By Source
  • Natural Psychedelic Substance
  • Synthetic Psychedelic Substance
By Drug Type
  • Gamma Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Lysergic Acid Diethylamide
  • 3,4-MethylEnedioxyMethamphetamine
  • Others
By Application
  • Treatment-Resistant Depression
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Narcolepsy & Panic Disorder
  • Others
By Distribution Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Frequently Asked Questions

The psychedelic therapeutics market was valued at USD 2,840.6 million in 2022 and is expected to grow at a 13.9% CAGR from 2023 to 2029.

The growing interest in alternative drugs and their development in the treatment of mental disorders with less side effects is expected to provide opportunities to the market players in the market growth over the forecast period.

The leading players in the global Psychedelic Therapeutics market are Janssen Global Services LLC, Jazz Pharmaceuticals Inc., Hikma Pharmaceuticals PLC, Verrian, Pfizer Inc., F. Hoffmann-La Roche Ltd, Avadel, Celon Pharma SA, Cybin Corp, GH Research, Entheon Biomedical Corp, PharmaTher Holdings Ltd., NRx Pharmaceuticals.

The psychedelic therapeutics market is segmented based on source, drug type, application, distribution channel and geography.

  • Janssen Global Services LLC
  • Jazz Pharmaceuticals Inc.
  • Hikma Pharmaceuticals PLC
  • Verrian
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd
  • Avadel
  • Celon Pharma SA
  • Cybin Corp
  • GH Research
  • Entheon Biomedical Corp
  • PharmaTher Holdings Ltd
  • NRx Pharmaceuticals